Biotechnology company and drug delivery platform innovator
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning conveyed its support
for the Food & Drug Administration’s (“FDA”) February 21 statement titled
“Smoking Cessation and Related Indications: Developing Nicotine Replacement
Therapy Drug Products”. The FDA’s statement outlined the development of safe
and effective novel nicotine replacement therapies to help smokers quit
cigarettes, stating that “novel products with different characteristics or
routes of nicotine delivery have the potential to offer additional
opportunities for health-concerned smokers interested in quitting.” Lexaria
recently entered a partnership with a leading tobacco company to use
DehydraTECH(TM) technology to develop new oral nicotine products. This
technology could provide a nicotine delivery method that harmonizes with
current FDA policies while avoiding the grave health consequences related to
smoking cigarettes and preserving the consumers’ choice.
To view the full FDA statement, visit http://ibn.fm/4RIy8
To view the full press release, visit http://ibn.fm/eC8YC
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its DehydraTECH(TM)
delivery technology. Lexaria’s technology provides increases in intestinal
absorption rates; more rapid delivery to the bloodstream; and important
taste-masking benefits, for orally administered bioactive molecules including
cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs),
nicotine and other molecules. For more information, visit the company’s website
at www.LexariaBioscience.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
